These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19082528)

  • 1. Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules.
    Inoue T; Fujita T; Kishimoto H; Makino T; Nakamura T; Nakamura T; Sato T; Yamazaki K
    J Bone Miner Metab; 2009; 27(1):66-75. PubMed ID: 19082528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate.
    Iwamoto J; Takeda T; Ichimura S
    J Orthop Sci; 2001; 6(6):487-92. PubMed ID: 11793169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin K to prevent fractures in older women: systematic review and economic evaluation.
    Stevenson M; Lloyd-Jones M; Papaioannou D
    Health Technol Assess; 2009 Sep; 13(45):iii-xi, 1-134. PubMed ID: 19818211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Menatetrenone for the treatment of osteoporosis.
    Iwamoto J; Sato Y
    Expert Opin Pharmacother; 2013 Mar; 14(4):449-58. PubMed ID: 23346882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
    Matsumoto T; Hagino H; Shiraki M; Fukunaga M; Nakano T; Takaoka K; Morii H; Ohashi Y; Nakamura T
    Osteoporos Int; 2009 Aug; 20(8):1429-37. PubMed ID: 19101754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy.
    Meunier PJ; Sebert JL; Reginster JY; Briancon D; Appelboom T; Netter P; Loeb G; Rouillon A; Barry S; Evreux JC; Avouac B; Marchandise X
    Osteoporos Int; 1998; 8(1):4-12. PubMed ID: 9692071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
    J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
    Chesnut CH; Silverman S; Andriano K; Genant H; Gimona A; Harris S; Kiel D; LeBoff M; Maricic M; Miller P; Moniz C; Peacock M; Richardson P; Watts N; Baylink D
    Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical treatment of vertebral osteoporosis.
    Lippuner K
    Eur Spine J; 2003 Oct; 12 Suppl 2(Suppl 2):S132-41. PubMed ID: 13680313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
    Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
    N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study.
    Shiraki M; Itabashi A
    J Bone Miner Metab; 2009; 27(3):333-40. PubMed ID: 19172219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
    Ettinger B; Black DM; Mitlak BH; Knickerbocker RK; Nickelsen T; Genant HK; Christiansen C; Delmas PD; Zanchetta JR; Stakkestad J; Glüer CC; Krueger K; Cohen FJ; Eckert S; Ensrud KE; Avioli LV; Lips P; Cummings SR
    JAMA; 1999 Aug; 282(7):637-45. PubMed ID: 10517716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of vertebral fractures by strontium ranelate in postmenopausal women with osteoporosis.
    Compston J
    Osteoporos Int; 2005 Jan; 16 Suppl 1():S4-6. PubMed ID: 15480571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
    Su S; He N; Men P; Song C; Zhai S
    Osteoporos Int; 2019 Jun; 30(6):1175-1186. PubMed ID: 30734066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.
    Reginster JY; Meurmans L; Zegels B; Rovati LC; Minne HW; Giacovelli G; Taquet AN; Setnikar I; Collette J; Gosset C
    Ann Intern Med; 1998 Jul; 129(1):1-8. PubMed ID: 9652994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
    Boonen S; McClung MR; Eastell R; El-Hajj Fuleihan G; Barton IP; Delmas P
    J Am Geriatr Soc; 2004 Nov; 52(11):1832-9. PubMed ID: 15507059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New spine and non-spine fractures in 871 women/year treated with oral pamidronate plus calcium and vitamin D supplements].
    Man Z; Otero AB
    Medicina (B Aires); 1997; 57 Suppl 1():32-6. PubMed ID: 9567352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
    Meunier PJ; Roux C; Ortolani S; Diaz-Curiel M; Compston J; Marquis P; Cormier C; Isaia G; Badurski J; Wark JD; Collette J; Reginster JY
    Osteoporos Int; 2009 Oct; 20(10):1663-73. PubMed ID: 19153678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.